About 30% products will be impacted by price control: Lupin

Mumbai based pharma company Lupin says any kind of price control will be a deterrent for the industry and 30 percent of its portfolio will be impacted if government implements price control measures.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

Nov 21, 2012, 03.30 PM | Source: CNBC-TV18

About 30% products will be impacted by price control: Lupin

Mumbai based pharma company Lupin says any kind of price control will be a deterrent for the industry and 30 percent of its portfolio will be impacted if government implements price control measures.

Like this story, share it with millions of investors on M3

About 30% products will be impacted by price control: Lupin

Mumbai based pharma company Lupin says any kind of price control will be a deterrent for the industry and 30 percent of its portfolio will be impacted if government implements price control measures.

Post Your Comments

Share Cancel

S Ramesh (more)

President, Finance & Planning, Lupin |

Mumbai-based pharma company Lupin says any kind of price control will be a deterrent for the industry and 30 percent of its portfolio will be impacted if government implements price control measures.

A group of ministers will meet on Wednesday to resolve the deadlock on the national pharma pricing policy. The GoM had earlier recommended market-based pricing for essential drugs and the government should control 30 percent of the market. The Finance Ministry in turn has recommended a cost-based pricing policy.

Meanwhile, Lupin expects to get a "pretty good" market share in the Fenofibrate anti-cholesterol drug Tricor (marketed by Abbott) segment, following the launch of its generic version on Tuesday.

The company's subsidiary Lupin Pharmaceuticals has launched Fenofibrate Tablets in 48mg and 145mg strengths in the US market.

Abbott's Tricor had sales of USD 1.26 billion, it said, citing IMS Health data for June.

Lupin also doesn't expect any significant threat to the already existing product Antara, which is also one of the fenofibrates.

The company had acquired the US rights for Antara (Fenofibrate capsules in 43mg and 130mg strength) in September 2009. It was earlier marketed by Oscient Pharmaceuticals.

Below is the edited transcript of the interview given to CNBC-TV18 by Ramesh- President- Finance & Planning, Lupin.

Q: What is your expectation in terms of monthly revenues from Tricor given the level of competition that you are working with and the kind of price erosion that you are likely to see?

A: Tricor is a 120 crore opportunity which is pretty large by generic standards. Given the fact that it is actually a three player market, today we have Teva, Lupin and potentially Valiant also. It is obviously going to be a limited competition market. So the price erosion is not going to be pretty high. Looking at our past track record of actually getting about 30-35 percent market share in anything that we get into, we would obviously expect us to get a pretty good market share in this particular molecule as well. So, we have pretty high expectations from Tricor.

1 2
Buy, Hold, Sell ? Hear it first on M3
About 30% products will be impacted by price control: Lupin

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login